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Background: Adenosine may have beneficial effects on left ventricular function after myocardial infarction (MI), but
the magnitude of this effect on remote and MI areas is controversial. We assessed the long-term effects of
adenosine after MI using electrocardiogram-triggered 18 F-fluorodeoxyglucose positron emission tomography.
Methods: Wistar rats were subjected to coronary ligation and randomized into three groups treated daily for
2 months by NaCl (control; n = 7), 2-chloroadenosine (CADO; n = 8) or CADO with 8-sulfophenyltheophilline, an
antagonist of adenosine receptors (8-SPT; n = 8).
Results: After 2 months, control rats exhibited left ventricular remodelling, with increased end-diastolic volume and
decreased ejection fraction. Left ventricular remodelling was not significantly inhibited by CADO. Segmental
contractility, as assessed by the change in myocardial thickening after 2 months, was improved in CADO rats
compared to control rats (+1.6% ± 0.8% vs. −2.3% ± 0.8%, p < 0.001). This improvement was significant in border
(+5.6% ± 0.8% vs. +1.5% ± 0.8%, p < 0.001) and remote (−4.0% ± 1.0% vs. −10.4% ± 1.3%, p < 0.001) segments, but
absent in MI segments. Histological analyses revealed that CADO reduced fibrosis, cardiomyocyte hypertrophy and
apoptosis. Protective effects of CADO were blunted by 8-SPT.
Conclusion: Long-term administration of adenosine protects the left ventricle from contractile dysfunction
following MI.
Keywords: Adenosine; Myocardial infarction; Contractility; Left ventricular remodelling; Gated cardiac positron
emission tomographyBackground
Despite reperfusion therapies, left ventricular (LV) re-
modelling occurs in many patients after acute myocar-
dial infarction (MI), leading to a risk of subsequent heart
failure [1]. This has stimulated efforts to develop new
pharmacological strategies to prevent or reverse LV remod-
elling. LV remodelling is defined as a complex sequence
of changes in left ventricle geometry and function
[2,3] involving progressive LV dilatation, cardiomyocyte
hypertrophy and fibrosis, ultimately leading to the loss of
contractile function and LV dysfunction. The long-term
outcome of acute MI patients largely depends on the
amount of the initial injury which conditions subsequent* Correspondence: yvan.devaux@crp-sante.lu
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reproduction in any medium, provided the origLV remodelling. Thus, therapeutic strategies aiming at
reducing infarct size and improving LV remodelling are of
major interest.
Adenosine is a ubiquitous endogenous nucleoside that
modulates physiological functions in various organs and
plays important roles within the cardiovascular system.
It can signal through four sub-types of G protein-
coupled receptors, all of which are expressed in the
heart [4]. Cardioprotective properties of adenosine have
been characterized, particularly during ischemic pre-
conditioning. However, the long-term effect of adenosine
after MI has received less attention.
Disappointing results were documented when adeno-
sine was administrated during the acute phase of
reperfused MI in humans [5-7]. However, further experi-
mental data suggest that beneficial effects could beThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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in a rat infarct model improved global LV function assessed
by echocardiography [8]. A recent study showed that infarct
size could be reduced by increasing adenosine levels in
transgenic swine through over-expression of ectonucleoside
triphosphate diphosphohydrolase-1 (CD39) [9].
While adenosine appears to have certain beneficial ef-
fects after MI, the mechanisms and sites of these effects,
as well as the consequences on global LV remodelling,
are poorly documented. Therefore, the aim of the
current study was to investigate the effects of long-term
administration of adenosine on LV function and remod-
elling after MI by serial non-invasive imaging with elec-
trocardiogram (ECG)-triggered 18 F-fluorodeoxyglucose
positron emission tomography (FDG-PET). FDG-PET
has been reported as an imaging technique for assessing
the severity and the location of MI and is also capable of
quantifying global and segmental LV function [10,11].
Thus, FDG-PET allows for a separate analysis of the
contractile function of MI, remote and border segments.
Methods
This study was performed in accordance with the regula-
tions of the Animal Welfare Act of the National Institutes
of Health Guide for the Care and Use of Laboratory
Animals (NIH Publication No. 85-23, revised 1996), and
protocols were approved by the Regional Veterinary
Department (‘Direction Départementale de la Protection
des Populations’), agreements RAR1A03516811825 and
54–100.
Animal model and experimental design
Twenty-three adult male Wistar rats (282- to 335-g body
weight at the beginning of the study; Charles Rivers
Laboratories, Wilmington, MA, USA) were enrolled. All
animals were housed on a 12-h light-dark cycle in a
room with temperature and humidity control, and with
ad libitum access to tap water and standard rodent food.
Permanent occlusion of the left anterior descending
(LAD) coronary artery was performed in 23 rats as pre-
viously described [10,12]. The choice of this model ra-
ther than a model of ischemia/reperfusion was based on
preliminary experiments suggesting that adenosine may
be more protective in large infarcts than small infarcts
(not shown). Rats were anaesthetized by inhalation of an
isoflurane/oxygen mixture (2% to 3%:1.5% v/v) and were
intubated and ventilated with a rodent ventilator
(Harvard Apparatus, Holliston, MA, USA). The heart
was exposed through a left lateral thoracotomy of the
fifth intercostal space. After pericardial incision, the
proximal part of the LAD (2 to 3 mm from the top of
the left atrium) was ligated with a 7-0 Prolene suture
(Ethicon, Somerville, NJ, USA). Perioperative lidocaine
(10 mg/kg, Aguettant, Lyon, France) was used to providea local anaesthesia and to reduce the incidence of ven-
tricular tachycardia and fibrillation. Finally, the chest
was closed in layers with a 2-0 Vicryl suture (Ethicon,
Somerville, NJ, USA), the lungs were reinflated using
positive-end expiratory pressure, and the endotracheal
tube was removed once spontaneous breathing had
resumed. Amoxicillin was injected intramuscularly
(60 mg/kg, GlaxoSmithKline, Marly-le-Roi, France) to
avoid bacterial infections. The mortality of the proced-
ure was <20%.
Two days after surgery, rats were assessed by ECG-
triggered 18 F-FDG-PET. This first PET exam allowed
for randomizing the animals into three treatment groups
according to infarct size. This randomization was crucial
to avoid any bias due to different infarct sizes in experi-
mental groups. Infarct size is indeed a major determin-
ant of LV remodelling. A three-point classification was
used to determine MI size, as previously described by
our team [10]: small MI (no more than 3 among the 17
LV segments), moderate MI (4 to 5 segments) and large
MI (at least 6 MI segments). Groups were constituted in
order to exhibit equivalent rates of rats with small, moder-
ate and large MI. In each of the three groups, rats were
assigned to treatment with NaCl (control group; n = 7) or
2-chloroadenosine (2 mg/kg/day), a stable analogue of ad-
enosine, which was given alone (CADO group; n = 8) or
with 8-sulfophenyltheophilline (10 mg/kg/day), an antag-
onist of adenosine receptors (8-SPT group; n = 8). NaCl,
CADO and 8-SPT (Sigma-Aldrich, Bornem, Belgium)
were administered intraperitoneally twice daily for
2 months, starting 7 days after the date of LAD occlusion.
18 F-Fluorodeoxyglucose PET
Two days, 1 month and 2 months after surgery, LV func-
tion and infarct size were assessed in vivo by FDG-PET.
As already described in detail elsewhere [10,13], rats re-
ceived an oral pre-medication of 50 mg/kg of acipimox,
a potent nicotinic acid derivative yielding high-quality
cardiac FDG-PET images. Around 74 MBq of 18 F-FDG
(IBA, Nancy, France) were injected intravenously under
a transient anaesthesia with isoflurane. A 16-min record-
ing was started 1 h later on a high-resolution dedicated
small animal PET system (Inveon, Siemens, Knoxville, TN,
USA) and under continuous anaesthesia by isoflurane. Im-
ages were reconstructed in 16 cardiac intervals with a 3-D
ordered subset expectation maximization algorithm lead-
ing to a voxel size of 0.8 × 0.4 × 0.4 mm.
FDG uptake was determined on the set of collapsed
short-axis slices in each segment from the 17-segment
LV division from the American Heart Association [14]
with the QGS software [15]. LV end-diastolic volume
(EDV), LV end-systolic volume (ESV) and ejection frac-
tion (EF) were obtained from the set of contiguous
ECG-triggered short-axis slices with the QGS software
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was previously demonstrated on phantoms from LV rats
above the level of 100 μL, corresponding to the lower
limit for the LV end-systolic volume in adult rats [13].
The QGS software was also used for assessing the con-
tractility of each of the 17 LV segments according to the
percentage of systolic increase in myocardial countsFigure 1 Examples of FDG-PET images at 48 h, 1 month and 2 month
shown at both end-diastole (ED) and end-systole (ES), and segmental cont
ED and ES. Counts are represented through a colour scale, which is display
(100%) is represented in white, 50% is in blue and less than 10% is in black
which reflects contractile function, was marked outside the MI area (white
2 months for CADO rats, but was clearly affected for control and 8-SPT rats
with expansions of infarct areas (red arrows) and increases in LV volumes.[15]. This parameter is strongly linked to the percentage
of myocardial thickening with both myocardial SPECT
and TEP imaging techniques [17,18].
As previously described and validated [10], all seg-
ments for which the average FDG uptake was very low
(<50% of the maximal voxel value) could be considered
as predominantly necrotic, and the percentage of suchs in representative cases. Horizontal and vertical long-axis slices are
ractility is assessed through the increase in myocardial counts between
ed on the right side of the figure and where the maximal count level
. The change in the colour of myocardial walls from ED to ES images,
arrows) for the three rats at baseline. This change was unaffected at
. Global LV remodelling was similar in the three experimental groups,
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the segmental analysis of LV contractility, MI segments
were defined as those showing a very low FDG uptake
(<50% of the maximal voxel value) on the entire segment
area, remote segments were defined as those which were
not adjacent to any segment showing such a low uptake,
and the remaining segments were considered to be
within the border zone.
The average heart rate value during PET acquisition
was extracted from the list mode recording data. Systolic
blood pressure was calculated as the mean value of four
recordings by the tail-cuff method during the PET acqui-
sition (AD Instruments, Powerlab, Paris, France).Histological analyses
Rats were sacrificed 1 to 2 days after the last 2 months of
PET acquisition with an overdose of sodium pentobarbital.
The hearts were excised, snap frozen in liquid nitrogen,
fixed and embedded in optimal cutting media (VWR,
Fontenay-sous-Bois, France). Contiguous sections (8 μm),








Extent of MI area (% of LV) 35 ± 6 32 ± 15 32 ± 21
EDV (μL) 412 ± 61 397 ± 57 441 ± 66
ESV (μL) 239 ± 48 230 ± 43 257 ± 74
EF (%) 42 ± 7 42 ± 6 42 ± 7
1 month
Extent of MI area (% of LV) 32 ± 9 29 ± 14 33 ± 23
Change from 48 h −3 ± 7 −3 ± 4 1 ± 7
EDV (μL) 600 ± 95 576 ± 111 666 ± 175
Change from 48 h 188 ± 76 179 ± 120 225 ± 160
ESV (μL) 353 ± 67 324 ± 106 428 ± 185
Change from 48 h 114 ± 61 94 ± 112 171 ± 149
EF (%) 42 ± 2 45 ± 9 38 ± 12
Change from 48 h 0 ± 8 3 ± 10 −5 ± 7
2 months
Extent of MI area (% of LV) 30 ± 11 26 ± 15 32 ± 27
Change from 48 h −5 ± 9 −7 ± 8 0 ± 9
EDV (μL) 692 ± 132 637 ± 151 780 ± 232
Change from 48 h 280 ± 113 241 ± 158 339 ± 212
ESV (μL) 432 ± 120 379 ± 149 530 ± 210
Change from 48 h 19 ± 99 149 ± 145 273 ± 174
EF (%) 38 ± 5 42 ± 8 34 ± 10
Change from 48 h −4 ± 6 0 ± 8 −9 ± 6LV (depending on infarct location), were obtained in a
cryostat at −22°C and stored at −80°C until analysis.
The degree of fibrosis in heart sections was assessed by
Masson's trichrome staining. The collagen volume frac-
tion was measured while omitting fibrosis of the perivas-
cular, epicardial and endocardial areas [19]. The fibrosis
area in the border zone was measured in three random
fields per heart section (×400 magnification) by dividing
the area of collagen to the total area and using ImageJ ver-
sion 1.42 (http://rsbweb.nih.gov/ij/index.html).
Haematoxylin and eosin staining was performed to as-
sess the cross-sectional area of cardiomyocytes in heart
sections. For each section, at least five cardiomyocytes
sectioned transversely were randomly chosen, and their
area was quantified using ImageJ software. The average
area was calculated for each experimental group.
Immunohistochemical staining was performed for
annexin-5 apoptosis marker using a rabbit polyclonal
antibody (Abcam, Cambridge, UK). Alexa Fluor® 635-
coupled goat anti-rabbit antibody was used as secondary
antibody (Invitrogen, Merelbeke, Belgium). Technical
controls without primary antibody were performed for
each marker to ensure staining specificity. DAPI was
used to reveal nuclei. Images were recorded on a confocal
microscope (Zeiss Laser Scanning Microscope LSM 510,








Body weight (g) 312 ± 25 307 ± 35 307 ± 20
Systolic blood pressure (mmHg) 104 ± 3 107 ± 8 102 ± 7
Heart rate (bpm) 419 ± 14 403 ± 38 422 ± 21
1 month
Body weight (g) 353 ± 22 332 ± 30 332 ± 27
Change from 48 h 41 ± 15 25 ± 14 25 ± 22
Systolic blood pressure (mmHg) 106 ± 4 106 ± 4 104 ± 4
Change from 48 h 2 ± 4 −2 ± 8 2 ± 7
Heart rate (bpm) 374 ± 31 338 ± 35* 335 ± 48
Change from 48 h −45 ± 36 −66 ± 69 −87 ± 60
2 months
Body weight (g) 402 ± 12 363 ± 26* 376 ± 45
Change from 48 h 90 ± 22 56 ± 29 69 ± 43
Systolic blood pressure (mmHg) 104 ± 4 104 ± 3 104 ± 5
Change from 48 h 0 ± 5 −3 ± 6 2 ± 10
Heart rate (bpm) 383 ± 22 338 ± 33* 353 ± 39
Change from 48 h −36 ± 27 −66 ± 44 −68 ± 36
*p < 0.05 for unpaired comparisons vs. control group.
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(Carl Zeiss Microscopy, Oberkochen, Germany).
Statistical analysis
Analyses were performed using the SAS R9.3 software
(SAS Institute, Cary, NC, USA), and the two-tailed sig-
nificance level was set to p < 0.05.
Pairwise comparisons of quantitative variables between
the CADO or 8-SPT group and the control group were
carried out using the Mann-Whitney test, and corre-
sponding variables were expressed with mean ± standard
error of the mean (SEM).
Segmental contractility was analysed over time using
repeated measures mixed ANOVA: (1) with treatmentFigure 2 CADO treatment improves segmental contractile function in
the three experimental groups is expressed as the change from 48 h to 1 a
evolution of segmental contractility (i.e. whole heart). (B, C) Evolution of se
location (MI, border zone or remote area). Data are adjusted mean ± SEM. *group and segment location as fixed factors and (2)
with rat as a random factor nested within the ‘treat-
ment’ variable (all segments from a single rat received
the same treatment). The results of these analyses were
expressed as adjusted means ± SEM. Validity conditions
of the models were thoroughly checked (normality of
residuals, homoscedasticity and absence of collinearity
or interaction). These global analyses were conducted
for assessing, first, the effect of CADO alone (CADO
vs. control) and, thereafter, the effect of CADO associ-
ated with 8-SPT (8-SPT vs. control). In order to pre-
serve the overall 5% alpha error rate, the comparisons
of CADO or 8-SPT vs. control were carried out at the
2.5% level.remote regions after MI. The evolution of segmental contractility in
nd 2 months of the percentage of myocardial thickening. (A) Global
gmental contractility after 1 and 2 months according to segment
p < 0.01; **p < 0.001.
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Early FDG-PET imaging and randomization
Representative FDG-PET images obtained at 48 h, 1 month
and 2 months are shown in Figure 1. On the baseline FDG-
PET scans recorded 2 days after coronary occlusion, nec-
rotic segments were observed in all 23 animals. According
to the three-point classification of MI size (small, moderate
and large MI) [10], rats were subsequently randomized into
three treatment groups: control (n = 7), CADO (n = 8) and
8-SPT (n = 8). Thus, the mean infarct size was equivalent
between the three groups (Table 1). The mean baseline
values of LV volumes, LV ejection fraction, heart rate, blood
pressure and body weight were also similar between the
three groups (Tables 1 and 2).
Evolution of body mass, hemodynamic parameters and
global LV function
During the 2-month follow-up, all rats showed an in-
crease in body weight, a decrease in heart rate and a
stable level of systolic blood pressure. At 2 months,
however, body weight and heart rate were slightly but
significantly lower in CADO-treated rats than in control
rats (Table 2).
As detailed in Table 1, control rats exhibited marked
LV remodelling during the 2-month follow-up, as
attested by increased EDV and ESV, and decreased EF.
These changes were not significantly different in theFigure 3 8-SPT treatment aggravates cardiac fibrosis. Upper panel: car
Masson's trichrome. Representative pictures from the three experimental g
analysis of collagen volume fraction in non-infarcted areas. Results are meaCADO group or in the 8-SPT group, even though there
were trends toward a beneficial effect on LV volumes
and EF in the CADO group and a detrimental effect on
LV volumes and EF in the 8-SPT group (Table 1).
Evolution of segmental contractility
Seventeen segments were analysed in each of the 23 ani-
mals, leading to a total of 391 analysed segments. On
the 2-day FDG-PET exams, 43 segments were totally
necrotic (MI segments), 109 were considered as remote
segments and the 239 remaining segments were consid-
ered to be within the border zone. Myocardial thicken-
ing, assessed through the percentage of systolic increase
in myocardial counts, exhibited a continuous decline be-
tween remote (40% ± 9%), border zone (23% ± 13%) and
MI (12% ± 4%) segments (p < 0.001).
Analyses of variance revealed that the evolution of
myocardial thickening over 2 months was enhanced in
CADO-treated rats, compared to control rats, with a sig-
nificant interaction by segment location (remote, border
zone or MI area) (p = 0.03). In contrast, no difference
was observed when 8-SPT rats were compared to con-
trol rats using the same model.
Changes in segmental contractility from baseline were
also compared between the three groups at the specific
time-points of 1 and 2 months, as detailed in Figure 2.
The main observation was that, on average, thediac sections of non-infarcted areas of the left ventricle stained with
roups are shown. Magnification, ×400. Lower panel: quantitative
n ± SEM. **p < 0.001.
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rats was enhanced when compared to controls at 1 and
2 months (Figure 2A). After 1 month, the increase of
myocardial thickening was +3.8% ± 0.7% in the CADO
group compared to +0.9% ± 0.7% in the control group
(p < 0.01). After 2 months, contractile function was im-
paired in control rats, as attested by a decrease of myo-
cardial thickening of −2.3% ± 0.8%, and preserved in
CADO-treated rats (+1.6% ± 0.8%, p < 0.001). This effect
of CADO was blunted by 8-SPT (Figure 2A).
Interestingly, the beneficial effect of CADO on con-
tractile function varied according to segment location,
both after 1 month (Figure 2B) and after 2 months
(Figure 2C). In particular, at 2 months, this effect was
obvious (1) in the border zone where CADO rats
exhibited a significant increase in contractile function
(+5.6% ± 0.8%), whereas control rats did not (+1.5% ±
0.8%, p < 0.001 vs. CADO), and (2) in remote segments
where a decline in contractile function was docu-
mented in all groups but to a lower extent in the
CADO group (−4.0% ± 1.0%) than in the control group
(−10.4% ± 1.3%, p < 0.001 vs. CADO). By contrast, the
contractile function of MI segments was stable andFigure 4 CADO treatment limits cardiomyocyte hypertrophy. Upper p
and eosin in remote areas showing cardiomyocyte hypertrophy. Lower panel
remote areas. Cardiomyocyte hypertrophy was decreased in CADO-treated ra
*p < 0.005; **p < 0.001. Magnification, ×400.comparable in the two groups at 2 months (CADO +3.4%±
2.0% vs. control +2.0%± 1.8%, p=NS).
The beneficial effect of CADO on the contractile func-
tion of the border and remote segments was lost for rats
additionally treated with 8-SPT (Figure 2A,B).Fibrosis, cardiomyocyte hypertrophy and apoptosis
We examined the extent of fibrosis outside the MI areas
(Figure 3). CADO appeared to reduce fibrosis in remote
areas, when compared to controls, although this differ-
ence did not reach the level of statistical significance.
However, this fibrosis was markedly increased by the ad-
ministration of 8-SPT (eightfold increase compared to
the CADO group, p < 0.001).
The cardiomyocyte cross-sectional area in healthy
parts of the heart was lower in the CADO than in the
control group, and this effect was blunted by 8-SPT
(Figure 4).
Annexin-5 staining was reduced in CADO rats com-
pared to control rats and was robustly increased by 8-
SPT (Figure 5). These differences were evident in the
remote and border zones.anel: representative histological sections stained with haematoxylin
: quantitative analysis of the cross-sectional area of cardiomyocytes from
ts compared to control rats. Results are mean ± SEM. au, arbitrary units.
Figure 5 CADO treatment reduces apoptosis. Representative
pictures of annexin-5 immunostaining in the remote, border and
infarct (MI) zones are shown. Annexin-5 staining appears in pink, and
nuclei are coloured in blue by DAPI. CADO reduced apoptosis and
8-SPT exacerbated apoptosis, particularly in the border zone.
Magnification, ×400.
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induced fibrosis, cardiomyocyte hypertrophy and apoptosis.Discussion
Using FDG-PET in a rat infarct model, the present study
shows that adenosine provides beneficial effects within
the remote and border zones, but not within the MI
area. However, these effects have a limited impact on
global LV remodelling.
We have previously shown that the method of
acipimox-enhanced FDG-PET provides cardiac imagesof a very high quality in rats [13], as well as accurate as-
sessments of LV function and of MI size and location in
the experimental model of LAD occlusion [10]. In the
present study, the FDG-PET exams, performed 48 h
after surgery, allowed for randomizing the animals into
different treatment groups according to initial infarct
size. This size, which is highly variable in the rat model,
constitutes a main determinant of subsequent LV re-
modelling in the rat model [10]. Therefore, such a pre-
therapeutic randomization was critical for providing an
accurate comparison with the control group. This was
not done in the previous echocardiographic study of
long-term adenosine A2B receptor stimulation [8].
In addition, the FDG-PET technique allowed for a sep-
arate survey of the contractile function of the MI, re-
mote and border segments. These data showed that
treatment with CADO was beneficial on the contractile
function of the segments lying outside the MI area.
CADO treatment inhibited the progressive decline in
the contractile function of remote areas and enhanced
the contractile function within the border zone. These
effects were truly attributable to the stimulation of ad-
enosine receptors since they were abolished when a pan-
antagonist of adenosine receptors was added to CADO
treatment (8-SPT group).
The observation of a protective effect in the border
zone is clinically relevant since the border zone is con-
sidered as a main therapeutic target after MI. For in-
stance, injection of stem cells into the border zone has
been shown to enhance vascular density and contractile
performance in animals [20]. Similar results were ac-
hieved by the co-expression of vascular endothelial
growth factor and angiopoietin-1 in the infarct border
zone [21]. In addition, we have previously shown that
the perfusion of the infarct border zone was enhanced
after the injection of stem cells within the infarct core
[22]. However, these therapeutic approaches are not easy
to apply, whereas the present study shows that a simple
pharmacological treatment is able to improve myocardial
contractility.
The exact mechanism by which the stimulation of ad-
enosine receptors improves contractile function in the
border and remote zones remains to be fully defined.
We observed a mild lowering of heart rate after 2 months
of CADO treatment, but this is unlikely to fully explain
the cardioprotective effects of CADO. Previous in vitro
experiments from our group have shown that adenosine
regulates multiple pathways involved in LV remodelling,
such as inflammation, angiogenesis and extracellular
matrix turnover [23-26]. In the present in vivo study, we
further extend the cardioprotective properties of adeno-
sine to apoptosis, consistent with a previous report by
Simonis et al. [27], fibrosis [8] and cardiomyocyte hyper-
trophy [28]. All together, these results suggest that
Bousquenaud et al. EJNMMI Research 2013, 3:65 Page 9 of 10
http://www.ejnmmires.com/content/3/1/65therapeutic targeting of adenosine receptors may have
multiple cardioprotective effects.
Angiotensin-converting enzyme (ACE) inhibitors and
beta-blockers are currently used to limit LV remodelling
after MI. Although their effects on global function and
on the limitation of infarct expansion are well docu-
mented [29], their effects in the border zone are still
poorly known. Beta-blockers may only have a limited ef-
fect in the border zone because of multiple defects in
the membrane beta-adrenergic receptor complex in the
infarcted heart [30]. Our results, showing a preservation
of contractile function in remote and border zones, but
no effect on the infarct area, suggest that adenosine may
target other signalling pathways than ACE inhibitors and
beta-blockers. Whether adenosine exerts complementary
cardioprotective effects to ACE inhibitors and beta-
blockers could be the subject of further studies.
In our study, CADO was unable to significantly pro-
tect the heart from the development of adverse LV re-
modelling, as assessed by LV volumes and EF. These
results differ from those of Wakeno and colleagues [8],
where a selective adenosine A2B receptor agonist was
reported to prevent LV remodelling after MI. In that
study, LV function was assessed in only two dimensions
by echocardiography and there was no documentation
that the different experimental groups had equivalent in-
farct size before treatment. A2B receptors play critical
roles in the reduction of remodelling and in the revascu-
larization of the infarcted heart induced by mesenchymal
stem cells [31]. Activation of A2B receptors inhibits
apoptosis after MI [27]. However, a specific blockade of
A2B receptors has been also shown to limit LV remodel-
ling after MI [32]. The cardioprotective properties of
A2B receptors are therefore complex and have been re-
cently reviewed [33].
The roles of A1 and A3 receptors are also multiple
and complex in this setting. Initial studies by Matherne
and colleagues indicated that activation of the A1 adeno-
sine receptor protects from myocardial ischemia [34].
This observation was subsequently confirmed by other
groups (reviewed in [35]). The failure of CADO, a pref-
erential A1 receptor agonist, to protect from LV remod-
elling in our study might be related to A3 activation,
which has shown deleterious cardiac effects [36]. On the
opposite, the A3 receptor has also cardioprotective prop-
erties [37].
Finally, all four sub-types of adenosine receptors ap-
pear to have the potential to exert cardioprotective ef-
fects after ischemia. Adenosine has multiple effects on
several components of LV remodelling such as inflam-
mation, fibrosis, angiogenesis, apoptosis, etc. These ef-
fects rely on the sub-type of adenosine receptors present
on the cell surface. It remains to be determined whether
the activation or blockade of several sub-types ofadenosine receptors has superior anti-remodelling ef-
fects than the preferential activation of one receptor. It
will also be interesting in future studies to address the
cardioprotective effects of adenosine in a model of ische-
mia/reperfusion, which more closely resembles the clin-
ical MI setting.
Conclusions
We have shown that, when administrated long-term
after MI, adenosine exerts beneficial effects on the myo-
cardial contractility of remote and border zones, but
with limited impact on global LV remodelling. Further
studies are required to determine the therapeutic poten-
tial of this observation.
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